Scarica l'app Stockscreener
145.70
3.84%
5.39
Dopo l'orario di chiusura:
145.70
Precedente Chiudi:
$140.31
Aprire:
$141.49
Volume 24 ore:
152.93K
Relative Volume:
0.58
Capitalizzazione di mercato:
$2.09B
Reddito:
$1.30M
Utile/perdita netta:
$-49.30M
Rapporto P/E:
-34.95
EPS:
-4.1688
Flusso di cassa netto:
$-25.01M
1 W Prestazione:
-4.66%
1M Prestazione:
+34.08%
6M Prestazione:
+44.21%
1 anno Prestazione:
+485.14%
Intervallo 1D:
$138.29
$147.96
Intervallo di 1 settimana:
$135.00
$150.40
Portata 52W:
$24.07
$161.38
Palvella Therapeutics Inc Stock (PVLA) Company Profile
Nome
Palvella Therapeutics Inc
Settore
Industria
Telefono
(484) 253-1461
Indirizzo
353 W. LANCASTER AVENUE, WAYNE
Compare PVLA vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PVLA
Palvella Therapeutics Inc
|
145.70 | 2.01B | 1.30M | -49.30M | -25.01M | -4.1688 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.93 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.50 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Palvella Therapeutics Inc Stock (PVLA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-07 | Iniziato | Mizuho | Outperform |
| 2025-12-05 | Iniziato | BTIG Research | Buy |
| 2025-12-04 | Iniziato | Craig Hallum | Buy |
| 2025-11-19 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2025-09-09 | Iniziato | Oppenheimer | Outperform |
| 2025-08-06 | Iniziato | Raymond James | Outperform |
| 2025-07-21 | Iniziato | Truist | Buy |
| 2025-04-09 | Iniziato | Chardan Capital Markets | Buy |
| 2025-03-26 | Iniziato | Stifel | Buy |
| 2025-03-07 | Iniziato | Scotiabank | Sector Outperform |
| 2025-02-20 | Iniziato | Canaccord Genuity | Buy |
| 2025-02-05 | Iniziato | TD Cowen | Buy |
| 2024-12-26 | Iniziato | H.C. Wainwright | Buy |
| 2024-12-18 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-03-13 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2019-07-30 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2019-05-14 | Iniziato | Robert W. Baird | Outperform |
| 2018-03-19 | Iniziato | Evercore ISI | Outperform |
| 2018-03-19 | Iniziato | Jefferies | Buy |
| 2018-01-16 | Reiterato | H.C. Wainwright | Buy |
| 2017-05-30 | Iniziato | Rodman & Renshaw | Buy |
| 2016-08-05 | Ripresa | ROTH Capital | Buy |
| 2015-08-12 | Iniziato | JMP Securities | Mkt Outperform |
| 2015-07-27 | Iniziato | Oppenheimer | Outperform |
| 2015-07-22 | Iniziato | ROTH Capital | Buy |
Mostra tutto
Palvella Therapeutics Inc Borsa (PVLA) Ultime notizie
PVLAPalvella Therapeutics Inc Volatility & Greeks - Finviz
Price to book forward of Palvella Therapeutics, Inc. – NASDAQ:PVLA - TradingView
Mizuho Securities Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $240 - Moomoo
Palvella Therapeutics Adds Rare Disease Executive Matt Pauls to Board of Directors - citybiz
Palvella Therapeutics, Inc. Files Form 8-K: Key Company Details, Stock Info, and Contact Information (June 2026) - Minichart
Palvella Therapeutics appoints Matt Pauls to board of directors By Investing.com - Investing.com South Africa
Palvella Therapeutics appoints Matt Pauls to board of directors - Investing.com
Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors - The Globe and Mail
Palvella Therapeutics Appoints Accomplished Rare Disease - GlobeNewswire
Palvella Therapeutics stock hits 52-week high at 151.36 USD - Investing.com
Palvella Therapeutics stock hits 52-week high at 151.36 USD By Investing.com - Investing.com Nigeria
Palvella Therapeutics, Inc.(NasdaqGM: PVLA) dropped from Russell 3000E Index - marketscreener.com
Palvella Therapeutics, Inc.(NasdaqGM: PVLA) dropped from Russell Microcap Index - marketscreener.com
Palvella submits FDA NDA for QTORIN gel - grafa.com
Palvella submits first module of NDA for rare skin disease therapy - Investing.com
Palvella Therapeutics Submits First Rolling NDA Module for QTORIN Rapamycin in Microcystic Lymphatic Malformations - Quiver Quantitative
Palvella Therapeutics Submits First Module of Rolling New - GlobeNewswire
Palvella Therapeutics, Inc.(NasdaqGM:PVLA) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
Palvella Therapeutics, Inc.(NasdaqGM: PVLA) dropped from Russell 3000 Value Benchmark - marketscreener.com
Palvella Therapeutics, Inc.(NasdaqGM: PVLA) dropped from Russell 2500 Value Benchmark - marketscreener.com
Palvella Therapeutics, Inc.(NasdaqGM:PVLA) dropped from Russell 3000E Value Benchmark - marketscreener.com
Palvella Therapeutics, Inc.(NasdaqGM:PVLA) dropped from Russell 3000E Growth Benchmark - marketscreener.com
What to Know About This $476,000 Palvella Therapeutics Insider Sale After a 620% Stock Rally - Yahoo Finance
What to Know About This $476,000 Palvella Therapeutics Insider Sale After a 620% Stock Rally - The Motley Fool
Price to earnings forward of Palvella Therapeutics, Inc. – NASDAQ:PVLA - TradingView
Palvella Therapeutics, Inc. Actuals & Estimates (NASDAQ:PVLA) - TradingView
Palvella Therapeutics Inc (PVLA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Palvella Therapeutics, Inc. Actuals & Estimates (LS:A40RA6) - TradingView
Canaccord reiterates Palvella stock rating on physician survey data - Investing.com UK
Enterprise value to revenue forward of Palvella Therapeutics, Inc. – LS:A40RA6 - TradingView
Enterprise value to EBIT forward of Palvella Therapeutics, Inc. – NASDAQ:PVLA - TradingView
A40RA6 Forecast — Price Target — Prediction for 2027 - TradingView
Palvella shares advance after FDA grants rolling review for rare disease therapy - MSN
Price to earnings forward of Palvella Therapeutics, Inc. – LS:A40RA6 - TradingView
Canaccord reiterates Palvella stock rating on physician survey data By Investing.com - Investing.com South Africa
Palvella Therapeutics Insiders Placed Bullish Bets Worth US$850.0k - Moomoo
CCORF Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $227 - Moomoo
Price to sales forward of Palvella Therapeutics, Inc. – NASDAQ:PVLA - TradingView
Price to book forward of Palvella Therapeutics, Inc. – LS:A40RA6 - TradingView
Enterprise value to EBITDA forward of Palvella Therapeutics, Inc. – LS:A40RA6 - TradingView
Stifel Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $250 - Moomoo
Craig-Hallum Reaffirms Their Buy Rating on Palvella Therapeutics (PVLA) - The Globe and Mail
Palvella Therapeutics COO Kathleen Goin sells $476,372 in stock By Investing.com - Investing.com India
Palvella stock rises on FDA rolling review for rare disease drug - Investing.com
Form 4 Palvella Therapeutics Inc For: 22 June By Investing.com - Investing.com Nigeria
Palvella Therapeutics COO Kathleen Goin sells $476,372 in stock - Investing.com
Palvella Therapeutics granted FDA rolling review for QTORIN - grafa.com
Palvella Therapeutics Inc Azioni (PVLA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Palvella Therapeutics Inc Azioni (PVLA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Goin Kathleen | Chief Operating Officer |
Jun 17 '26 |
Sale |
110.73 |
4,302 |
476,373 |
0 |
1.18%
2.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):